Ultra-LEAF™ Purified anti-human IGFBP-4 Antibody

Pricing & Availability
A15038E (See other available formats)
Regulatory Status
Other Names
Insulin-like growth factor-binding protein 4, IBP4
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
Recombinant human IGFBP-4 binds human IGF-I in a dose-dependent manner (black circles). The binding of human IGF-I to human IGFBP-4 is blocked (purple circles) by increasing concentrations of anti-human IGFBP-4 monoclonal antibody (Clone A15038E). The ND50 is typically 4 - 12 µg/mL.
  • A15038E_ULEAF_IGFBP-4_Block_Antibody_052217
    Recombinant human IGFBP-4 binds human IGF-I in a dose-dependent manner (black circles). The binding of human IGF-I to human IGFBP-4 is blocked (purple circles) by increasing concentrations of anti-human IGFBP-4 monoclonal antibody (Clone A15038E). The ND50 is typically 4 - 12 µg/mL.
Cat # Size Price Quantity Check Availability Save
697403 100 µg $270
Check Availability

Need larger quantities of this item?
Request Bulk Quote
697404 1 mg $715
Check Availability

Need larger quantities of this item?
Request Bulk Quote

Human IGFBP-4 was initially cloned from the human placenta, liver, and ovary cDNA libraries. Seven IGFBPs has been described that modulate the IGF activity. IGFBPs structurally are characterized by three domains: the amino-terminal, the carboxyl-terminal, and an intermediate variable L-domain. Some IGFBPs bind to the extracellular matrix (IGFBP-2, -3, and -5) or the cell membrane (IGFBP-1, -2, -3, and -5). The IGF binding activity of IGFBP-4 is mainly localized in the N-terminal region. IGFBP-4 is the smallest IGFBP, and there is no evidence for cell surface or ECM association of IGFBP-4. In addition, it contains an N-linked glycosylation site and exists in biological fluids as a doublet of 24 kD nonglycosylated and a 28 kD glycosylated forms. IGFBP-4 binds both IGF-I and IGF-II with similar affinities. Nevertheless, it is generally coexpressed with IGF-II during development. Proteolysis is the main regulatory mechanism of IGFBP-4 activity. Pregnancy-associated plasma protein-A (PAPP-A) was identified as an IGF-dependent IGFBP-4 protease. It belongs to the metzincin superfamily of metalloproteinases and cleaves IGFBP-4 at a single site. IGFBP-4 has potent IGF-independent anti-angiogenic and antitumorigenic effects, activities that are located in the C-terminal, and a region containing a thyroglobulin type 1 (Tg1) domain.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Antibody Type
Host Species
Recombinant human IGFBP4
0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.01 EU/µg of the protein (<0.001 ng/µg of the protein) as determined by the LAL test.
The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Blocking - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by blocking activity. The ND50 is 4 - 12 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.

AB_2687181 (BioLegend Cat. No. 697403)
AB_2687182 (BioLegend Cat. No. 697404)

Antigen Details


It is expressed in a variety of tissues and cells such as embryonic and postnatal brain, human osteoblast-like cells, skin fibroblasts, endothelial cells, epithelial cells, intestinal epithelium, and in a variety of tumor cells.

IGFBP-4 inhibits the action of IGFI and II by preventing their binding to their receptors. The binding affinity of IGFBP-4 for IGFs is regulated by proteolysis through PAPP-A.
Biology Area
Angiogenesis, Cancer Biomarkers, Cell Biology, Cell Proliferation and Viability
Antigen References

1. Shimasaki S, et al. 1990. Molecular Endocrinol. 4:1451.
2. Boldt HB, et al. 2001. Biochem. J. 358:359.
3. Bunn RC and Fowlkes JL. 2003. Trends Endocrinol. Metab. 14:176.
4. Ning Y, et al. 2008. Mol. Endocrinol. 22:1213.
5. Moreno MJ, et al. 2013. Neoplasia. 5:554.
6. Contois LW, et al. 2012. J. Biol. Chem. 287:1779.
7. Shi Z, et al. 2013. Am. J. Physiol. Gastrointest. Liver Physiol. 305:G74.

Gene ID
3487 View all products for this Gene ID
View information about IGFBP-4 on UniProt.org

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Go To Top Version: 0    Revision Date: 05/26/2017

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.


*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.


8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Ultra-LEAF™ Purified anti-human IGFBP-4


Remember me
Forgot your password? Reset Password
Request an Account